Tolmar patents expiration
1. Eligard Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9283282 | TOLMAR | Sustained release polymer |
Oct, 2018
(5 years ago) | |
| US8486455 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US9254307 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US9539333 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US9914802 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(6 months ago) | |
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395293 | TOLMAR | Biodegradable implant precursor |
Sep, 2013
(10 years ago) | |
| US5599552 | TOLMAR | Biodegradable polymer composition |
Feb, 2014
(10 years ago) | |
| US6773714 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US6565874 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US6626870 | TOLMAR | Stoppering method to maintain sterility |
Mar, 2020
(4 years ago) | |
| US8840916 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 24 July, 2002
Treatment: Method of treating cancer; Palliative treatment of prostate cancer
Dosage: POWDER;SUBCUTANEOUS
ELIGARD KIT family patents
2. Fensolvi Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9539333 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US9914802 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(6 months ago) | |
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-829) | May 01, 2023 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 01 May, 2020
Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty
Dosage: POWDER;SUBCUTANEOUS
FENSOLVI KIT family patents
3. Jatenzo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11179402 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Apr, 2026
(1 year, 11 months from now) | |
| US10617696 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11331325 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Jan, 2027
(2 years from now) | |
| US8241664 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Mar, 2029
(4 years from now) | |
| US8778916 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US11426416 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US11179403 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US10543219 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US8492369 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Dec, 2030
(6 years from now) | |
| US11564933 | TOLMAR | Methods of treating testosterone deficiency |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: Method of treating testosterone deficiency; A method of treating testosterone deficiency in men; Testosterone replacement therapy in males for conditions associated with a deficiency or absence of end...
Dosage: CAPSULE;ORAL
JATENZO family patents